1 of Wall Street’s favorite stocks to own for decades and 2 facing challenges

Several stocks have recently gained significant attention from Wall Street, with analysts projecting returns exceeding 20%. However, investors are advised to approach these predictions cautiously, as analysts often express positive sentiments to attract business for their firms in other areas, such as mergers and acquisitions advisory. At StockStory, we prioritize independent analysis to assess whether these optimistic forecasts are substantiated. Here, we highlight one stock that appears to be a solid investment according to Wall Street, alongside two others facing considerable challenges.

Carrier Global (CARR) is one stock that analysts recommend selling. The company, established by the inventor of air conditioning, specializes in manufacturing products for heating, ventilation, air conditioning, and refrigeration. The consensus price target for Carrier Global stands at $73.01, suggesting a potential return of 29.8%. Despite this positive outlook, there are several concerns regarding its performance. Over the past two years, the company's organic sales growth has been lackluster, indicating a potential need for strategic changes or mergers and acquisitions to stimulate faster growth. Additionally, its earnings per share (EPS) have declined over the same period, raising alarms among investors since stock prices generally follow EPS trends in the long run. Furthermore, decreasing returns on capital suggest that the company’s previous profit sources may be diminishing. Currently, Carrier Global's shares are priced at $56.25, reflecting a forward price-to-earnings ratio of 18.5. For more insights, interested investors can access our free research report on Carrier Global.

Another stock that analysts recommend avoiding is Surgery Partners (SGRY). The company operates a national network of outpatient surgical facilities, including ambulatory surgery centers and short-stay surgical hospitals, with over 180 locations across 33 states. The consensus price target for Surgery Partners is $18.82, indicating a 21% implied return. However, the company has faced disappointing unit sales in the past two years, suggesting that demand is weak and prompting a potential need for strategic reevaluation. Analysts forecast a 5.5% decline in sales over the next year as demand continues to wane. Additionally, Surgery Partners has a high net-debt-to-EBITDA ratio of 7x, which could force the company to seek capital under unfavorable conditions if the market deteriorates further. As of now, Surgery Partners is trading at $15.55 per share, translating to a forward P/E ratio of 59.2. Prospective investors are encouraged to read our free research report to understand the risks associated with this stock.

On a more positive note, ITT (ITT) is a stock that analysts support as a buy. The consensus price target for ITT is set at $257.77, implying a potential return of 37%. This company has historical significance, having played a vital role in the development of the first transatlantic television transmission in 1956. ITT specializes in providing motion and fluid handling equipment for various industries, positioning itself as a crucial player in its field. The combination of its strong fundamentals and favorable outlook makes ITT an attractive option for investors looking to expand their portfolios.